Ovarian cancer
Results
Phase 3
This trial looked at olaparib and cediranib after chemotherapy for ovarian cancer that had started to grow again after initial treatment.
It was for women who had:
ovarian cancer
fallopian tube cancer
primary peritoneal cancer
Doctors treat these cancers in the same way. So, when we use the term ovarian cancer in this summary, we are referring to all 3.
This trial was supported by Cancer Research UK. It was open for women to join between 2018 and 2023. The team presented the first set of results at a conference in 2024.
Recruitment start: 1 August 2018
Recruitment end: 20 February 2023
Please note: In order to join a trial you will need to discuss it with your doctor, unless otherwise specified.
Dr Shibani Nicum
Cancer Research UK
AstraZeneca
University College London
Stand Up To Cancer
Gynecologic Cancer InterGroup
Canadian Cancer Trials Group (CCTG)
Australia New Zealand Gynaecological Oncology Group (ANZGOG)
European Network of Gynaecological Oncology Trials groups (ENGOT)
National Cancer Research Institute (NCRI)
This is Cancer Research UK trial number CRUK/15/074.
Last reviewed: 11 September 2025
CRUK internal database number: 13388
About Cancer generously supported by Dangoor Education since 2010. Learn more about Dangoor Education
What to ask your doctor about clinical trials.
Meet and chat to other cancer people affected by cancer.
Questions about cancer? Call freephone 0808 800 40 40 from 9 to 5 - Monday to Friday. Alternatively, you can email us.
